CL2024002613A1 - Profármacos de decanoato de abiraterona y uso en terapia - Google Patents

Profármacos de decanoato de abiraterona y uso en terapia

Info

Publication number
CL2024002613A1
CL2024002613A1 CL2024002613A CL2024002613A CL2024002613A1 CL 2024002613 A1 CL2024002613 A1 CL 2024002613A1 CL 2024002613 A CL2024002613 A CL 2024002613A CL 2024002613 A CL2024002613 A CL 2024002613A CL 2024002613 A1 CL2024002613 A1 CL 2024002613A1
Authority
CL
Chile
Prior art keywords
abiraterone
decanoate
prodrugs
therapy
disorder
Prior art date
Application number
CL2024002613A
Other languages
English (en)
Spanish (es)
Inventor
j sharp Matthew
R Moore William Jr
Original Assignee
Propella Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Propella Therapeutics Inc filed Critical Propella Therapeutics Inc
Publication of CL2024002613A1 publication Critical patent/CL2024002613A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2024002613A 2022-03-01 2024-08-30 Profármacos de decanoato de abiraterona y uso en terapia CL2024002613A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263315240P 2022-03-01 2022-03-01
US202263425839P 2022-11-16 2022-11-16

Publications (1)

Publication Number Publication Date
CL2024002613A1 true CL2024002613A1 (es) 2025-02-07

Family

ID=85724851

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002613A CL2024002613A1 (es) 2022-03-01 2024-08-30 Profármacos de decanoato de abiraterona y uso en terapia

Country Status (12)

Country Link
US (1) US20250186463A1 (cg-RX-API-DMAC7.html)
EP (1) EP4486353A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025508944A (cg-RX-API-DMAC7.html)
KR (1) KR20240167653A (cg-RX-API-DMAC7.html)
CN (1) CN119136813A (cg-RX-API-DMAC7.html)
AU (1) AU2023229152A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243913A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002613A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024013267A2 (cg-RX-API-DMAC7.html)
IL (1) IL315174A (cg-RX-API-DMAC7.html)
MX (1) MX2024010741A (cg-RX-API-DMAC7.html)
WO (1) WO2023167783A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021338271A1 (en) * 2020-09-02 2023-03-30 Astellas Us Llc Abiraterone prodrugs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
AU2019362061B2 (en) 2018-10-18 2024-09-26 Essa Pharma Inc Androgen receptor modulators and methods for their use
CN114026106B (zh) * 2019-03-06 2025-01-21 普洛拉治疗公司 阿比特龙前药
CN117120034A (zh) 2021-02-15 2023-11-24 普洛佩拉治疗公司 阿比特龙前药
WO2023038933A1 (en) * 2021-09-08 2023-03-16 Propella Therapeutics, Inc. Oral abiraterone formulations

Also Published As

Publication number Publication date
MX2024010741A (es) 2024-09-10
CA3243913A1 (en) 2023-09-07
IL315174A (en) 2024-10-01
CO2024013267A2 (es) 2024-10-10
WO2023167783A1 (en) 2023-09-07
US20250186463A1 (en) 2025-06-12
CN119136813A (zh) 2024-12-13
EP4486353A1 (en) 2025-01-08
KR20240167653A (ko) 2024-11-27
AU2023229152A1 (en) 2024-09-05
JP2025508944A (ja) 2025-04-10

Similar Documents

Publication Publication Date Title
MX2021010553A (es) Profarmacos de abiraterona.
DOP2022000128A (es) Compuestos y métodos para la degradación dirigida del receptor de andrógenos
CY1125358T1 (el) Θεραπεια συνδυασμου η οποια περιλαμβανει εναν mdm2 αναστολεα και εναν ή περισσοτερους επιπροσθετους φαρμακευτικως δραστικους παραγοντες για την αντιμετωπιση καρκινων
CO2024013267A2 (es) Profármacos de decanoato de abiraterona y uso en terapia
CO2021009882A2 (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer
UY38700A (es) Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
CO2024013243A2 (es) Conjugado de anticuerpo b7h4-farmaco y su uso
MX419719B (es) Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos.
MX2023002478A (es) Profarmacos de abiraterona.
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
AR057941A1 (es) Agentes terapeuticos para el cancer de prostata
BR112021014636A2 (pt) Uso de imunoconjugados anti-ceacam5 para tratamento de câncer de pulmão
CL2019002871A1 (es) Terapia combinada para cáncer de próstata.
CO2025008047A2 (es) Conjugados de anticuerpo ceacam5-fármaco y métodos de uso de los mismos
CL2020002637A1 (es) Métodos de tratamiento de cáncer.
BR112022000120A2 (pt) Projeto e sínteses eficientes de conjugados de lipídeo-fluoresceína para terapia de células car-t
MX2022009399A (es) Formulacion topica de roflumilast que tiene mayor liberacion y semivida plasmatica.
UY39368A (es) Composiciones para modular el empalme
MX2024003277A (es) Conjugado de anticuerpo-farmaco para usarse en metodos de tratamiento del cancer resistente a la quimioterapia.
MX2021012449A (es) Metodo para tratar tumores.
BR112022020592A2 (pt) Combinações antitumor contendo conjugados de anticorpo anti-ceacam5, trifluridina e tipiracila
AR119681A1 (es) Métodos de tratamiento del cáncer de mama con tucatinib
JOP20220292A1 (ar) صياغات صيدلانية من أسيتات أبيراتيرون ونيراباريب
MX2024012392A (es) Terapia combinada para el tratamiento del cancer
CO2025004508A2 (es) Conjugados de anticuerpo-farmaco dirigidos a glipicano-3 y métodos de uso